1. Volume 130, Issue 4, Pages 1054-1061 (April 2006)
Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial 
Marc LÉmann, Jean–Yves Mary, Bernard Duclos, Michel Veyrac, Jean–Louis Dupas, Jean Charles Delchier, David Laharie, Jacques Moreau, Guillaume Cadiot, Laurence Picon, Arnaud Bourreille, Iradj Sobahni, Jean–Frederic Colombel 
Gastroenterology 
Volume 130, Issue 4, Pages (April 2006)
DOI: /j.gastro
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

2. Figure 1
Flow chart of patients randomized in the trial. The figures in parentheses correspond to the number of patients in the naive stratum and the failure stratum, respectively.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

3. Figure 2
Percent of patients in clinical remission and off steroids at weeks 12, 24 (primary end point), and 52 (follow-up evaluation). The figures below the bars correspond to the number of patients analyzed at each date. □, AZA/6-MP + placebo; ■, AZA/6-MP + infliximab 5 mg/kg.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

4. Figure 3
Percent of patients in clinical remission and off steroids in the 2 strata at weeks 12, 24 (primary end point), and 52 (follow-up evaluation). The figures below the bars correspond to the number of patients analyzed at each date. □, AZA/6-MP + placebo; ■, AZA/6-MP + infliximab 5 mg/kg.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions